the United States (U.S.) was home to both the first and the largest reported abdominal aortic aneurysm (AAA) screening programs to date. influenced by the results of four randomized trials conducted outside the U.S., the U.S. Preventive Services ta sk force (USPStf) recommended one-time AAA screening with ultrasound for men 65-75 years old who have ever smoked. After the USPStf report, the U.S. congress added a Medicare benefit forfree, one-timeAAA screeningwithultrasoundfor menwho havesmokedand for men and women with af amily history of AAA. Screening may be underutilized in this target population, but recommendations by American vascular societies for much broader use of screening and repair than can be justified by the available evidence are influencing practice and threaten the effectiveness and cost-effectiveness of AAA screening in the U.S.
demonstrationproject from the Minneapolis Ve terans Affairs (VA) Medical Center in 1988 (6), the VA ADAM group reported comparisons of ultrasound and health survey findings from 126196 veterans, the largest reported screening program to date (7).
The next milestone in AAA screening in the U.S. came in February 2005. Following publication of four randomized trials (all from outside the U.S.) which collectivelys howed thatu ltrasound screening was associated with as ignificant reduction in AAA-related mortality (8), the U.S. Preventive Services Task Force (USPSTF) recommended one-time AAA screening with ultrasound for men 65-75 years old who have ever smoked (9). The task force made no recommendation for men who had never smoked and recommended against routine screening for AAA in women.
Because Medicare, which provides health carecoverage for Americans over age 65, does not include preventive services, every new preventive benefit requires the proverbial act of Congress. After the USP-STFreport, theU.S.Congress addedaMedicarebenefit for AAA screening which went into effect on January 1, 2007. It provides af ree, one-time, ultrasound test for men who have smoked and for men and women with afamily history of AAA. The ultrasound test must be ordered at the "Welcome to Medi-Screening for abdominal aortic aneurysm (AAA) began in the United States (U.S.). An abstract in Circulation in 1966 by Schilling and colleagues (1) described the use of physical examination and lateral abdominal X-rays to detect AAA in men aged 55-64 in seven U.S. cities. Morethan 3% of the 873 men screened had AAA, and the authors recommended routine population screening (2). The next report of AAA screening, also from the U.S., was aN ovember 1983 paper by Cabellon and colleagues reporting use of ultrasound and abdominal palpation to find AAA in 7o f7 3a symptomatic patients with vascular disease( 3). That same month, Twomey et al. reported as creening study from Middlesex, England at the annual meeting of the Vascular Surgery Society of Great Britain and Ireland (4,5). Once the concept had crossed the Atlantic it found fertile ground, and reports of larger communitybased programs in the United Kingdom and Europe soon followed, including moret han a dozen articles from Dr Bergqvist and his colleagues in Uppsala. Meanwhile, back in the U.S., after asmall care Physical Exam", which itself must be completed within the first six months of Medicareeligibility (i.e., at age 65-65½). Probably as aresult of this extremely limited allowable age range, Medicarec laims are falling well short of the amount Congress earmarked for this purpose (10). The Society for Vascular Surgery is lobbying Congress to extend coverage throughout the 65-75 year age group recommended by USPSTF,inwhom screening is believed to remain underutilized (10) .
In August 2007, the U.S. VA Under Secretary informed VA facilities that men aged 65-75 who have ever smoked need to be offered one-time screening for AAA, preferably with ultrasound, unless they have already had imaging since age 60 or aren ot candidates for AAA repair.Adownloadable AAA screening reminder was provided for use with the VA's computerized medical record.
Now that AAA screening is widely available in the U.S., the question is whether the benefits seen in the randomized trials will be achieved in practice. The randomized trials that showed AAA screening to be effective and cost-effective employed strict criteria for screening eligibility.Moreimportantly,inthe Multi-centreA neurysm Screening Study (MASS) (11), the largest and most influential trial, AAA repair was not undertaken unless the AAA was 5.5 cm or larger,i n accordance with the earlier UKSAT( 12) and ADAM trial (13) findings. If AAA screening and/or repair wereemployed on amuch wider scale than occurred in the trials, the ratio of benefit to harm could be reduced or even reversed. This is the situation that may be developing in the U.S. Aconsensus statement published by three American vascular societies proposed criteria for screening eligibility much broader than those recommended by the USPSTF or used in the randomized trials of screening (14) . The vascular societies' criteria include men aged 60-85, women aged 60-85 with cardiovascular risk factors, and anyone over age 50 with afamily history of AAA, unless the subject is unfit for any intervention. Descriptions of several recent free ultrasound screening programs conducted in the U.S. have been published (Table 1) .
The Life Line program (17) used criteria very similar to those proposed by the vascular societies, whereas the AVA (15) and DARE to CARE (16) programs had only minimum age criteria. As shown in the Table, the majority of subjects screened in all three programs werew omen, despite afi ve-fold lower prevalence of AAA. The USPSTF had recommended against screening women because the only randomized trial to include women showed not only low prevalence but no favorable trend in AAA-related mortality.F ourteen percent of the DARE to CARE program screenees weree ither younger than 50 or older than 80 years of age. These reports suggest that the many screening programs operating in the U.S. outside of Medicareand the VA arelikely to be considerably less cost-effective than the randomized trials done in Europe.
Amuch moreconcerning threat to the effectiveness of screening is the tendency in the U.S. to repair small AAA. The Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery (18) , after acknowledging the findings of the UKSAT (12) and ADAM (13) trials that therew as no benefit from repair of AAA <5.5 cm in diameter,then recommended repair of smaller AAA in avariety of patient groups, including women, younger patients and patients of surgeons whose operative mortality rate is low,d espite early repair having been specifically shown in one or both trials to confer no benefit in each of these settings. Similarly,t he American College of Cardiology and the American Heart Association recently proffered the unsupported guideline that "Repair can be beneficial in patients with infrarenal or juxtarenal AAAs 5.0 to 5.4 cm in diameter" (19) , prompting ac ritical letter of response from the directors of the UKSATand ADAM trials (20) .
Given the recommendations of expert societies in the U.S. to repair AAA too small to benefit, it is not surprising that asimilar situation prevails in practice. For example, morethan 59% of patients treated with endovascular repair at the Cleveland Clinic between 1996 and 2002 had AAA smaller than 5.5 cm (21) . Each year in the U.S., 45,000 intact AAA arerepaired with an in-hospital mortality of 3.1%, resulting in 1400 deaths (22) . About 4500 deaths areattributed to AAA rupturei nt he U.S. each year (23) , indicating that deaths caused by elective repair constitute nearly aq uarter of all AAA mortality.I fs creening in the U.S. leads to alarge increase in elective repair in patients whose AAA would never have ruptured, the expected benefit of screening on AAA-related mortality may never be realized. 
